Fractional CMO for MedTech: What CEOs Actually Need to Know
A MedTech company does not hire a fractional CMO because it needs more marketing activity.
It hires one because growth has become too important, too expensive, or too complicated to leave without senior ownership.
That usually happens when the company has some combination of product-market traction, meaningful acquisition spend, regulatory constraints, multiple agencies, a growing commercial team, board pressure, or an upcoming financing or transaction.
The central question is not:
“Should we hire an agency or a fractional CMO?”
It is:
“Who owns the growth system?”
This guide explains what that ownership looks like in MedTech, when fractional leadership makes sense, where agencies fit, and what CEOs should expect from the first 90 days.
Why MedTech Growth Needs Senior Ownership
MedTech marketing sits at the intersection of commercial pressure and regulatory reality.
A growth plan may involve:
- FDA-cleared or approved products
- clinical evidence and claims
- physician adoption
- patient acquisition
- payer or reimbursement strategy
- hospital or enterprise sales
- consumer demand generation
- privacy and data governance
- agency execution
- board and investor reporting
No single campaign solves that.
Someone has to decide how the parts fit together.
That is the leadership gap a fractional CMO is meant to fill.
What a Fractional CMO Actually Does in MedTech
1. Defines the Commercial Strategy
The CMO should be able to answer basic questions the organization often avoids:
- Who is the highest-value buyer?
- Who is the user?
- Who influences adoption?
- What problem are we truly solving?
- Which claims can we defend?
- Which channel should lead growth?
- Where is the bottleneck?
- What should we stop funding?
Without those answers, agencies and internal teams are forced to make strategy through execution.
2. Connects Marketing to Economics
MedTech CEOs do not need more dashboards. They need a commercial model.
That may include:
- CAC by channel
- lead-to-opportunity rate
- sales-cycle length
- close rate
- contribution margin
- payback period
- retention or repeat use
- reimbursement economics
- revenue by customer segment
The right metrics depend on the business model. A DTC device, enterprise diagnostic platform, hospital-sold device, and subscription telehealth product should not be evaluated with the same scorecard.
3. Builds a Claims and Approval Process
Strong healthcare marketing is not timid. It is defensible.
For medical devices, leadership should make sure marketing language accurately reflects the product's regulatory status and intended use. FDA materials distinguish terms such as registered, cleared, approved, and authorized, and those terms should not be used interchangeably.
FTC guidance also makes clear that health-related advertising must be truthful, not misleading, and supported by adequate substantiation, including implied claims.
That means the CMO should help create a practical system where marketing, regulatory, legal, and clinical stakeholders know:
- which claims are approved
- what evidence supports them
- which qualifications are required
- what language is off limits
- who signs off before launch
The goal is not bureaucracy. The goal is avoiding expensive rework and weak claims governance.
4. Leads Agencies Instead of Replacing Them
Agencies can be extremely valuable in MedTech.
They can bring media buying, creative, SEO, content, development, CRO, lifecycle, PR, and production capacity.
But an agency should not be forced to become the de facto CMO simply because nobody internally owns strategy.
The better model is:
CMO sets direction → agency executes → CMO evaluates the business result.
That keeps the agency in the lane where it is strongest.
5. Creates Board-Level Clarity
The board does not need a tour of ad platforms.
It needs to know:
- what is working
- what is not working
- where growth is constrained
- what marketing is costing
- what the company should invest in next
- which risks need attention
A fractional CMO should translate marketing into business language.
Fractional CMO vs Agency
This is not an either-or decision.
An Agency Is Usually Best For:
- channel execution
- creative production
- paid media
- SEO
- web development
- campaign testing
- specialized tactical work
A Fractional CMO Is Usually Best For:
- strategy ownership
- budget prioritization
- offer and positioning decisions
- agency leadership
- team design
- commercial metrics
- board communication
- cross-functional alignment
- growth-system accountability
When a company already has strong senior marketing leadership, an agency may be all it needs.
When nobody owns the system, adding another agency often adds activity without solving the underlying problem.
Fractional CMO vs Full-Time CMO
A full-time CMO makes sense when the organization needs daily executive ownership and has enough complexity to justify a permanent role.
A fractional model can make more sense when:
- the company needs senior leadership now
- the workload is substantial but not truly full time
- the CEO is still carrying marketing decisions
- the company is between leaders
- the company is preparing to scale
- the board wants stronger commercial discipline before committing to a permanent executive hire
The benefit is not simply lower cost.
The benefit is buying the right amount of executive capacity for the current stage.
When a MedTech Company Is Ready for Fractional Leadership
Common signals include:
- marketing spend is growing but confidence is falling
- agencies disagree about what the company should do
- sales blames marketing and marketing blames sales
- the CEO is still approving every campaign
- the company cannot clearly explain CAC or pipeline economics
- positioning changes every quarter
- the team has more tactics than priorities
- growth has stalled despite more activity
- the company is entering a new market or launching a new product
- a financing, diligence process, or board review is approaching
The common thread is not company size.
It is complexity.
The First 90 Days of a Strong Fractional CMO Engagement
Days 1–30: Diagnose
The first month should create clarity, not a flood of new campaigns.
The CMO should review:
- positioning
- offer
- product claims
- channel performance
- conversion paths
- sales handoff
- retention
- attribution
- agency performance
- team responsibilities
- commercial reporting
The output should be a prioritized view of what is actually constraining growth.
Days 31–60: Architect
Once the bottleneck is clear, the company needs a system.
That may include:
- new positioning
- channel priorities
- funnel changes
- claims governance
- agency briefs
- reporting standards
- team responsibilities
- budget reallocation
The objective is focus.
Days 61–90: Execute and Measure
By the third month, execution should be running against a much clearer operating model.
The CMO should be able to tell leadership:
- what changed
- what the early evidence says
- what should continue
- what should stop
- what the next major decision is
Good fractional leadership should make the company easier to run, not more dependent on the fractional executive.
What CEOs Should Ask Before Hiring a Fractional CMO
- What business problem will this person own?
- Are they an advisor or an operator?
- Have they led growth inside regulated markets?
- Can they understand acquisition economics?
- Can they lead agencies and internal teams?
- Can they work with regulatory, clinical, finance, and sales?
- Can they explain marketing to a board without hiding behind jargon?
- How do they determine what not to do?
- What does success look like in the first 90 days?
- How does the engagement eventually transition?
A fractional CMO should make decisions clearer.
If the pitch is mostly about tactics, channel hacks, or guaranteed outcomes, that is a warning sign.
Why Regulatory Fluency Matters, but Should Not Be Oversold
A CMO is not a replacement for regulatory counsel, privacy counsel, a compliance officer, or a clinical expert.
What the CMO should understand is how those functions affect commercial execution.
For example:
- marketing should not imply FDA endorsement where none exists
- claims should remain consistent with evidence and intended use
- health advertising requires adequate substantiation
- tracking and data practices need appropriate privacy review
- marketing teams need a repeatable approval process
That is commercial fluency, not practicing law.
Why This Matters for Investors and Boards
Investors are not buying a marketing plan. They are evaluating whether growth is understandable and repeatable.
A stronger commercial story has:
- clear positioning
- defensible claims
- known acquisition economics
- visible conversion bottlenecks
- disciplined channel allocation
- credible reporting
- a team that knows who owns what
A weak commercial story is often obvious before anyone opens the spreadsheet.
There are too many initiatives, too many vendors, too many metrics, and nobody can explain what is driving growth.
That is exactly the problem senior marketing leadership should solve.
Where Charles Kirkland Fits
Charles Kirkland works as an operator-led fractional CMO and growth strategist for healthcare, medical device, telehealth, and regulated health businesses.
His background includes serving as CMO of Launch Medical and SkinStylus, leading growth teams, managing paid acquisition, building offers and funnels, and directing agencies across regulated health markets.
The emphasis is not on selling more marketing activity.
It is on identifying the constraint, creating a clear growth architecture, and helping the company execute against it.
What Changed in This 2026 Version
This guide was rebuilt in August 2026.
The previous version was more than 15,000 words and included stale 2025 framing, duplicated sections, unsupported salary and valuation claims, invented case studies, aggressive ROI language, and several overly broad statements about FDA, FTC, and HIPAA requirements.
Those have been removed.
The current version focuses on the durable buyer questions a MedTech CEO actually needs answered.
Primary Regulatory References
- FDA: Device Labeling
- FDA: Registered, Cleared, Approved, and Authorized Devices
- FTC: Health Products Compliance Guidance
- HHS: HIPAA and Online Tracking Technologies
Need to Know Whether the Problem Is Marketing or the Growth Architecture?
The Growth Clarity Diagnostic™ is designed to identify the real constraint across positioning, acquisition, conversion, economics, retention, attribution, team, and execution.
